Efficacy of IOP lowering drugs dependent on CCT

Article

Intraocular pressure (IOP) lowering drugs are more effective in eyes with low central corneal thickness (CCT) than those with high CCT, according to a study published in the March issue of Journal of Glaucoma.

Intraocular pressure (IOP) lowering drugs are more effective in eyes with low central corneal thickness (CCT) than those with high CCT, according to a study published in the March issue of Journal of Glaucoma.

Thomas V. Johnson of the University of Nebraska Medical Center, Nebraska, US, and colleagues conducted a retrospective study of 115 ocular hypertension (OHT) patients and 97 ocular normotensive (ONT) volunteers to determine the effect of CCT on the efficacy of topical IOP-reducing treatments.

Patients were divided into Thick (CCT >540 µm) and Thin (CCT ≤540 µm) categories (OHT, n=52, n=63 respectively; ONT, n=34, n=63 respectively). Measurements in the OHT group were made after washout of all IOP-lowering drugs and at one week of treatment with latanoprost 0.005%, dorzolamide 2%, brimonidine 0.2%, apraclonidine 0.5%, pilocarpine 2%, or unoprostone 0.15% to one eye and vehicle contralaterally.

One week following treatment, IOP was significantly lower in the OHT Thin group than the OHT Thick group (16.0±3.0 mmHg and 17.4±2.8 mmHg, respectively). Drug-treated eyes showed a positive correlation between IOP and CCT, which was not evident in vehicle-treated or untreated (ONT) eyes.

As the OHT Thin group demonstrated lower IOPs than the OHT Thick group following treatment, the researchers concluded that eyes with thinner corneas respond more positively to IOP lowering drugs than do eyes with thicker corneas.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.